Last updated: November 2, 2026
VISTASEAL is a fibrin sealant biologic marketed by Ethicon, a Johnson & Johnson MedTech company. The product contains human fibrinogen and human thrombin and is used as an adjunct to surgical hemostasis when conventional techniques are ineffective or impractical. VISTASEAL benefits from hospital formulary placement, surgeon familiarity, and procedural demand, but its financial performance is not separately disclosed by Johnson & Johnson. Its principal commercial risks are competition from other fibrin sealants, hospital purchasing pressure, manufacturing complexity, and substitution by mechanical or synthetic hemostatic products.
What is VISTASEAL and how does it work?
VISTASEAL is a topical fibrin sealant consisting of two human-plasma-derived proteins:
| Attribute |
VISTASEAL |
| Active components |
Human fibrinogen and human thrombin |
| Product type |
Biologic fibrin sealant |
| Sponsor and marketer |
Ethicon, Inc., a Johnson & Johnson MedTech company |
| FDA regulatory pathway |
Biologics license application |
| FDA application |
BLA 761092 |
| Initial U.S. approval |
2017 |
| Primary use |
Adjunct to hemostasis during surgery |
| Dosage forms |
Frozen fibrin sealant kits in multiple fill volumes |
| Administration |
Topical application, including spray delivery |
| Main customers |
Hospitals, ambulatory surgical centers, surgeons, group purchasing organizations |
When the two components are combined at the surgical site, thrombin converts fibrinogen into fibrin. The resulting clot supports local hemostasis. VISTASEAL is used across surgical settings where bleeding control is difficult or where sutures, cautery, compression, or ligation are insufficient.
The product is differentiated from mechanical hemostats because it is a biologically active sealant rather than a passive matrix. It competes with both other fibrin products and non-fibrin technologies.
What is the FDA status of VISTASEAL?
The FDA approved VISTASEAL in April 2017 under BLA 761092. The approved indication covers use as an adjunct to hemostasis during surgery, including when bleeding from capillaries, veins, and small arteries cannot be controlled effectively by conventional methods.
The FDA-approved label identifies the product as a human plasma-derived biologic. Relevant safety considerations include hypersensitivity, thrombosis risk if administered intravascularly, air or gas embolism associated with pressurized spray delivery, and transmission risks associated with plasma-derived materials. Ethicon uses donor screening, viral testing, and manufacturing controls to mitigate infectious-disease risk.[1]
VISTASEAL does not have the regulatory profile of a conventional small-molecule drug. Its market protection is not based on the standard five-year new chemical entity exclusivity framework, and generic substitution through an ANDA is not the relevant pathway.
What is the Orange Book status of VISTASEAL?
VISTASEAL is not expected to have a conventional Orange Book listing because it is licensed as a biologic rather than approved as a small-molecule drug through an NDA.
The relevant regulatory framework is the Public Health Service Act and the FDA’s biologics pathway. A competing manufacturer seeking approval of a highly similar product would generally pursue a biosimilar or interchangeable biosimilar pathway, although fibrin sealants present technical and clinical challenges that differ from those of monoclonal antibodies.
The absence of a conventional Orange Book listing has several commercial consequences:
- No standard Paragraph IV certification process applies.
- Generic substitution is not governed by ordinary state pharmacy substitution rules.
- Patent disputes are less likely to follow the classic Hatch-Waxman litigation model.
- Hospital contracting, clinical evidence, manufacturing reliability, and pricing become more important competitive variables.
When does VISTASEAL lose exclusivity?
A definitive loss-of-exclusivity date cannot be established from the public regulatory record alone. VISTASEAL’s market protection depends on several overlapping factors:
| Protection layer |
Commercial relevance |
| Regulatory exclusivity |
Biologic exclusivity associated with the reference product |
| Composition and manufacturing patents |
May protect the product, process, or component characteristics |
| Delivery-system patents |
May cover spray or dual-component administration systems |
| Trade secrets |
May protect purification, formulation, viral inactivation, and fill-finish processes |
| Manufacturing capacity |
Can delay competitive entry even after legal exclusivity expires |
| Hospital contracts |
Can preserve demand through purchasing relationships |
For a biologic approved in 2017, the statutory reference-product exclusivity period is generally shorter than the practical commercial life of a complex plasma-derived product. The major entry barrier is likely to be the combination of analytical comparability, clinical validation, donor-plasma sourcing, manufacturing controls, and hospital adoption rather than a single expiration date.
Publicly available information does not establish a complete, authoritative list of VISTASEAL patent numbers, expiration dates, terminal disclaimers, or continuing patent litigation. The product therefore should not be analyzed using an assumed single patent expiry date.
Are there Paragraph IV challenges or biosimilar risks for VISTASEAL?
No conventional Paragraph IV challenge is associated with VISTASEAL in the manner used for NDA products. A biosimilar entrant would need to demonstrate high similarity to a complex combination of human fibrinogen and thrombin, including relevant structural, functional, purity, and potency attributes.
The principal biosimilar risks are:
- Analytical comparability. Fibrinogen and thrombin are biologically active proteins with multiple quality attributes.
- Source-material control. Plasma collection, donor qualification, viral testing, and supply consistency are material barriers.
- Clinical evidence. A biosimilar applicant may need comparative clinical evidence in surgical settings.
- Delivery compatibility. The delivery device and mixing process can affect performance.
- Hospital adoption. Surgeons may resist switching products if bleeding-control performance is perceived to be procedure-critical.
- Pricing economics. A biosimilar must absorb development and manufacturing costs in a market where the reference product may be protected by contracts and brand familiarity.
Biosimilar competition is possible, but the risk is more likely to develop gradually than through an immediate generic launch. The competitive threat from alternative hemostatic products may arrive earlier than a directly substitutable biosimilar.
What products compete with VISTASEAL?
VISTASEAL competes in the broader surgical hemostasis market rather than in a narrow one-product category.
Direct fibrin-sealant competitors
Key competitors include:
- TISSEEL, marketed by Baxter, a fibrin sealant containing human fibrinogen and human thrombin.
- EVICEL, marketed by Ethicon, another human fibrin sealant used in surgical hemostasis.
- ARTISS, a fibrin sealant primarily used for tissue adhesion and graft fixation.
- Other regional and hospital-sourced fibrin products.
VISTASEAL and EVICEL have overlapping commercial positioning because both are Ethicon products. The portfolio relationship may allow Johnson & Johnson to offer differentiated products by procedure, delivery format, and hospital preference.
Indirect competitors
Indirect substitutes include:
- Oxidized regenerated cellulose products.
- Gelatin-based hemostats.
- Bovine or recombinant thrombin products.
- Collagen-based hemostats.
- Polysaccharide powders.
- Synthetic sealants.
- Fibrin sealant patches.
- Electrosurgery, sutures, clips, staples, and compression.
The purchasing decision often depends on the bleeding site, speed of hemostasis, application method, preparation time, storage requirements, and total procedure cost.
What formulations and delivery systems are protected by VISTASEAL?
VISTASEAL is supplied as a two-component system that combines fibrinogen and thrombin at the point of use. The product is available in multiple kit sizes and can be applied through a spray system.
The commercial value of the formulation and delivery system includes:
- Controlled separation of the two active components before use.
- Rapid preparation in the operating room.
- Consistent mixing during application.
- Multiple volume options for different procedures.
- Compatibility with topical or spray administration.
- Frozen storage and validated thawing procedures.
- Viral-reduction and plasma-processing controls.
Formulation and delivery patents may be more commercially significant than a basic composition claim because the active ingredients are established biological materials. However, a reliable public determination of the enforceable patent scope requires claim-level review of issued patents, continuations, maintenance fees, and ownership transfers.
How strong is the VISTASEAL patent estate?
VISTASEAL’s effective IP position is likely moderate to strong from a commercial standpoint, but it is difficult to quantify from publicly available information without a complete patent-family review.
Strengths
- Complex biologic manufacturing creates process barriers.
- Plasma sourcing and viral-safety controls are difficult to replicate quickly.
- Delivery-system integration can create additional patent and know-how protection.
- Hospital adoption and surgeon familiarity support brand durability.
- The product is embedded in a broader Ethicon surgical portfolio.
Weaknesses
- Fibrinogen and thrombin are established biological components.
- Competing fibrin sealants already exist.
- Alternative hemostats can avoid direct product imitation.
- A competitor may enter through a different formulation or delivery platform.
- Biologic exclusivity does not necessarily prevent all functional substitutes.
The strongest protection is likely a combination of regulatory know-how, manufacturing capability, supply agreements, and commercial relationships rather than a single composition patent.
What is the financial trajectory of VISTASEAL?
Johnson & Johnson does not separately report VISTASEAL revenue, gross margin, unit volume, or operating profit. The product is included within the company’s broader MedTech and Ethicon-related reporting.
Johnson & Johnson’s MedTech business generates annual revenue in the tens of billions of dollars, but the company reports results by major business area rather than by individual surgical product. VISTASEAL therefore cannot be assigned a verified standalone revenue trajectory from company filings.[2]
The product’s likely financial profile has several identifiable characteristics:
| Financial driver |
Effect on VISTASEAL |
| Procedure volumes |
Supports demand, particularly in inpatient and complex surgeries |
| Hospital budgets |
Creates price pressure and formulary review |
| Premium biologic pricing |
Supports revenue per procedure |
| Plasma and manufacturing costs |
Can constrain gross margin |
| Product mix |
Larger kits and spray systems may increase revenue per case |
| Ethicon sales force |
Supports cross-selling with surgical devices |
| Contracting |
Can protect volume but reduce net price |
| Competition |
Limits price expansion |
| Supply reliability |
Affects hospital retention and utilization |
Revenue growth is more likely to come from procedure penetration, conversion from competing hemostats, broader use in complex surgery, and product mix than from major increases in list price.
What is the revenue exposure for Johnson & Johnson?
VISTASEAL is unlikely to be financially material to Johnson & Johnson on a standalone basis relative to the company’s total revenue or MedTech segment. Its strategic value is greater than its disclosed revenue contribution because it supports Ethicon’s surgical-hemostasis portfolio and can be sold alongside other operating-room products.
The product can improve account economics by increasing the number of Ethicon products used in a procedure. Hospitals may evaluate VISTASEAL within a broader supplier relationship that includes stapling, energy, closure, wound-care, and other surgical technologies.
A material decline in VISTASEAL sales would likely have limited impact on consolidated Johnson & Johnson results but could affect the surgical-hemostasis category, Ethicon account-level performance, and portfolio positioning.
What generic launch scenarios exist for VISTASEAL?
Base case: continued branded leadership
Ethicon retains strong hospital access, and competitors remain focused on alternative hemostats rather than direct biosimilar entry. VISTASEAL maintains stable demand with moderate pricing pressure.
Downside case: formulary substitution
Hospitals impose lower-cost fibrin sealants or non-fibrin hemostats. VISTASEAL loses share in routine procedures while retaining use in complex surgeries where surgeon preference is strongest.
Disruption case: direct biologic competitor
A competing manufacturer establishes a sufficiently similar fibrin sealant with reliable supply, competitive pricing, and a validated delivery system. This would create pressure on contract pricing and rebate levels.
Supply-constrained case
Plasma availability, manufacturing interruptions, or quality events restrict supply. Hospitals shift temporarily to competing products, and some converted accounts may not return.
What patent litigation and settlement agreements affect VISTASEAL?
No major publicly established VISTASEAL-specific patent litigation or settlement agreement can be confirmed from the core FDA and Johnson & Johnson public materials. The absence of a known major dispute does not eliminate the possibility of private licensing, confidential settlements, or disputes involving related fibrin-sealant technologies.
Any future litigation would most likely involve:
- Formulation claims.
- Purification or viral-inactivation processes.
- Dual-syringe or spray delivery systems.
- Manufacturing methods.
- Trade-secret allegations.
- Contractual disputes involving plasma supply or hospital purchasing.
How does VISTASEAL compare with TISSEEL and EVICEL?
| Factor |
VISTASEAL |
TISSEEL |
EVICEL |
| Product class |
Human fibrin sealant |
Human fibrin sealant |
Human fibrin sealant |
| Primary market |
Surgical hemostasis |
Surgical hemostasis and tissue sealing |
Surgical hemostasis |
| U.S. sponsor |
Ethicon |
Baxter |
Ethicon |
| Main differentiation |
Ethicon delivery and surgical portfolio |
Baxter hemostasis portfolio and hospital presence |
Established Ethicon product position |
| Direct substitution risk |
High within fibrin sealants |
High within fibrin sealants |
High within fibrin sealants |
| Biosimilar complexity |
High |
High |
High |
| Commercial moat |
Manufacturing, contracts, surgeon familiarity |
Manufacturing, contracts, surgeon familiarity |
Manufacturing, contracts, surgeon familiarity |
VISTASEAL’s competitive position depends less on molecule-level novelty than on dependable operating-room performance, supply continuity, clinical familiarity, and integration into hospital purchasing systems.
Key Takeaways
- VISTASEAL is an Ethicon human fibrin sealant approved by the FDA in 2017 under BLA 761092.
- It contains human fibrinogen and human thrombin and is used as an adjunct to surgical hemostasis.
- It is not a conventional Orange Book product, and Paragraph IV litigation is not the normal competitive pathway.
- No verified standalone VISTASEAL revenue is disclosed by Johnson & Johnson.
- The product’s financial trajectory is tied to surgical procedure volumes, hospital contracting, product mix, and hemostasis-market competition.
- Direct competition comes from TISSEEL and EVICEL; indirect competition comes from mechanical, synthetic, collagen, gelatin, thrombin, powder, and patch-based hemostats.
- The principal barriers to biosimilar entry are analytical comparability, plasma sourcing, manufacturing validation, delivery-system performance, and hospital adoption.
- VISTASEAL’s effective commercial protection likely depends on a combination of regulatory status, manufacturing know-how, supply infrastructure, device integration, and hospital contracts.
- No major publicly established VISTASEAL patent litigation or settlement has been identified in the cited core sources.
- Johnson & Johnson’s consolidated financial exposure to VISTASEAL is likely limited, but the product supports Ethicon’s broader surgical portfolio.
FAQs about VISTASEAL
Is VISTASEAL a biologic or a medical device?
VISTASEAL is a biologic fibrin sealant. Its delivery system is a medical-device component, but the product is licensed by the FDA as a biologic.
Does VISTASEAL have a generic equivalent?
No conventional generic equivalent is established. A competing manufacturer would likely need to pursue a biologics pathway rather than an ordinary ANDA pathway.
Who manufactures VISTASEAL?
VISTASEAL is manufactured and marketed by Ethicon, Inc., part of Johnson & Johnson MedTech.
Is VISTASEAL derived from human plasma?
Yes. Its fibrinogen and thrombin components are derived from human plasma and undergo donor screening, testing, and viral-safety controls.
What is the largest commercial threat to VISTASEAL?
The largest near-term threat is likely hospital substitution among fibrin sealants and competing hemostatic technologies, rather than a rapid biosimilar launch.
References
-
U.S. Food and Drug Administration. (2017). VISTASEAL fibrin sealant (human): Prescribing information and biologics license application 761092. FDA.
-
Johnson & Johnson. (2025). 2024 annual report. Johnson & Johnson.
